Prognostic value and clinical usefulness of PIANO score in patients undergoing primary percutaneous coronary intervention

医学 传统PCI 经皮冠状动脉介入治疗 危险系数 内科学 临床终点 心肌梗塞 心脏病学 人口 置信区间 外科 临床试验 环境卫生
作者
Chunfeng Dai,Zheng Yang,Muyin Liu,You Zhou,Danbo Lu,Shufu Chang,Chenguang Li,Hao Lu,Zhangwei Chen,Juying Qian,Junbo Ge
出处
期刊:International Journal of Cardiology [Elsevier]
卷期号:390: 131258-131258 被引量:2
标识
DOI:10.1016/j.ijcard.2023.131258
摘要

Background In our previous study, the PIANO score was constructed to predict the occurrence of no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention (PCI). In the current analysis, we sought to evaluate the prognostic value and clinical usefulness of the PIANO score in this population. Methods Patients with acute myocardial infarction (AMI) undergoing primary PCI were consecutively enrolled and followed up in this register. The endpoint of interest was all-cause mortality at 2 years after the procedure. The clinical benefits of thrombus aspiration (TA) during primary PCI in certain subgroups were also evaluated as exploratory analyses. Results A total of 2100 patients were identified, and 54.3% had high (≥8) PIANO score. After 2-year follow-up, patients with high PIANO score had higher risk of all-cause mortality after adjustment for propensity score (6.7% vs. 3.1%, adjusted hazard ratio = 2.11 [1.21–3.68], p = 0.008), especially in the first month (adjusted hazard ratio = 2.33 [1.17–4.65], p = 0.017). Restricted cubic spline analysis indicated the linear association between the PIANO score and 2-year all-cause mortality (nonlinear p = 0.556). Further analysis demonstrated that TA did not reduce all-cause mortality in the overall patients, as well as in those with visible thrombus, high thrombus burden, or occlusive lesions. However, the PIANO score defined "high-risk" (PIANO score ≥ 8) patients could benefit from it. Conclusions The PIANO score had potential prognostic value in patients with AMI undergoing primary PCI. It might also be helpful for identifying patients who would benefit from TA. These observations require further confirmation in future studies.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
应急食品完成签到,获得积分10
刚刚
王博士完成签到,获得积分10
1秒前
2秒前
一水合羟基磷酸钙完成签到,获得积分10
2秒前
拼搏的春子完成签到,获得积分10
3秒前
叮咚jingle完成签到,获得积分10
3秒前
kyhappy_2002完成签到,获得积分10
3秒前
现代雪晴完成签到,获得积分10
3秒前
4秒前
777完成签到,获得积分10
4秒前
叶123完成签到,获得积分10
4秒前
风凌完成签到 ,获得积分10
5秒前
Foch完成签到,获得积分10
5秒前
Research完成签到 ,获得积分10
6秒前
zhaoXIN完成签到,获得积分20
6秒前
Rainbow完成签到,获得积分10
7秒前
Jiali完成签到,获得积分10
7秒前
kxxxxxx完成签到,获得积分20
8秒前
wanjunschem完成签到,获得积分10
9秒前
酚蓝8803完成签到 ,获得积分10
10秒前
心灵美书瑶完成签到,获得积分10
10秒前
马畅完成签到 ,获得积分10
11秒前
飞快的蛋完成签到,获得积分0
11秒前
11秒前
z7486完成签到,获得积分10
12秒前
忙碌的数学人完成签到,获得积分10
12秒前
肖旻完成签到,获得积分10
13秒前
lxg完成签到,获得积分10
13秒前
邵洋完成签到,获得积分10
13秒前
jj完成签到,获得积分10
15秒前
李健应助tianjiu采纳,获得10
15秒前
chen发布了新的文献求助10
15秒前
wanci应助XpenG采纳,获得10
15秒前
15秒前
肖旻发布了新的文献求助10
16秒前
轻松尔容完成签到 ,获得积分10
17秒前
顾乐乐完成签到,获得积分10
17秒前
将个烂就完成签到,获得积分10
18秒前
整齐百褶裙完成签到 ,获得积分10
18秒前
赘婿应助友好太兰采纳,获得10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Modern Epidemiology, Fourth Edition 5000
Handbook of pharmaceutical excipients, Ninth edition 5000
Digital Twins of Advanced Materials Processing 2000
Weaponeering, Fourth Edition – Two Volume SET 2000
Polymorphism and polytypism in crystals 1000
Signals, Systems, and Signal Processing 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 纳米技术 有机化学 生物化学 化学工程 物理 计算机科学 复合材料 内科学 催化作用 物理化学 光电子学 电极 冶金 基因 遗传学
热门帖子
关注 科研通微信公众号,转发送积分 6022031
求助须知:如何正确求助?哪些是违规求助? 7638908
关于积分的说明 16167722
捐赠科研通 5170058
什么是DOI,文献DOI怎么找? 2766661
邀请新用户注册赠送积分活动 1749784
关于科研通互助平台的介绍 1636740